Our Pricing

How to Switch From Ozempic to Wegovy or Mounjaro: UK Clinical Guidance

Many patients looking to switch from Ozempic to Wegovy or Mounjaro do so to access higher licensed doses for weight management or due to supply considerations. Both Wegovy (semaglutide) and Mounjaro (tirzepatide) are MHRA-licensed specifically for weight loss, whereas Ozempic is licensed for type 2 diabetes, making the transition a clinically appropriate step for those prioritising weight reduction outcomes. Understanding the dose conversion, expected timelines, and comparative efficacy helps ensure a safe and effective switch under UK prescriber supervision.

Why Patients Switch From Ozempic to Wegovy or Mounjaro

Patients commonly switch from Ozempic to Wegovy because both contain the same active ingredient—semaglutide—but Wegovy is licensed at higher maintenance doses (up to 2.4 mg weekly) specifically for chronic weight management [1]. Ozempic's maximum licensed dose is 1 mg weekly for diabetes, which may not deliver the same weight loss outcomes observed in the STEP clinical trial programme [1]. Switching to Wegovy allows continuation of semaglutide therapy at the evidence-based dose proven to achieve average weight reductions of 15-17% in clinical trials [1].

Alternatively, switching from Ozempic to Mounjaro introduces a dual-action GLP-1/GIP receptor agonist, tirzepatide, which demonstrated superior weight loss compared to semaglutide in head-to-head SURPASS-2 trial data [2]. Patients achieving suboptimal results on Ozempic may benefit from Mounjaro's dual incretin pathway, which produced average weight reductions exceeding 20% at the 15 mg maintenance dose [2]. Both switches require clinical assessment by a UK-registered prescriber to ensure suitability and appropriate dose titration.

Dose Conversion When You Switch From Ozempic to Wegovy

Because Wegovy and Ozempic share the same active ingredient, the dose conversion when switching from Ozempic to Wegovy is straightforward. If you are currently stable on Ozempic 1 mg weekly, UK clinical guidance typically recommends transitioning directly to Wegovy 1.7 mg weekly, then escalating to the target dose of 2.4 mg after four weeks [3]. This graduated approach minimises gastrointestinal side effects commonly associated with GLP-1 receptor agonists.

For patients on lower Ozempic doses (0.25 mg or 0.5 mg weekly), the switch from Ozempic to Wegovy should follow the standard Wegovy titration schedule, starting at 0.25 mg weekly and increasing every four weeks until reaching the 2.4 mg maintenance dose [3]. Your prescriber will tailor the schedule based on tolerance and treatment response. All dose adjustments must be supervised by a UK-registered healthcare professional to ensure safety and efficacy.

Timing Your Switch From Ozempic to Wegovy

Most UK prescribers advise administering your first Wegovy dose one week after your final Ozempic injection, maintaining the once-weekly rhythm without overlap [3]. Because semaglutide has a half-life of approximately one week, this interval prevents excessive drug accumulation while ensuring continuous GLP-1 receptor activity. Patients should not double-dose or shorten the interval without prescriber approval.

How to Switch From Ozempic to Mounjaro Safely

Switching from Ozempic to Mounjaro involves changing to a different active ingredient—tirzepatide—which acts on both GLP-1 and GIP receptors. UK clinical protocols recommend stopping Ozempic and initiating Mounjaro at the starting dose of 2.5 mg weekly, regardless of your previous Ozempic dose [4]. This conservative approach accounts for tirzepatide's distinct pharmacology and side effect profile, allowing your body to adjust to the dual incretin mechanism.

After four weeks on Mounjaro 2.5 mg, the dose is typically increased to 5 mg weekly, with further escalations every four weeks up to a maximum of 15 mg weekly, depending on treatment response and tolerability [4]. Clinical trial data from SURPASS-2 showed that tirzepatide 15 mg produced significantly greater weight loss than semaglutide 1 mg, with average reductions of 11.2 kg versus 5.7 kg over 40 weeks [2]. All patients switching from Ozempic to Mounjaro must complete an online clinical assessment with a UK-registered prescriber to confirm suitability and receive personalised dosing guidance.

Managing Side Effects When Switching From Ozempic to Mounjaro

Even though you have tolerated Ozempic, switching from Ozempic to Mounjaro may still cause transient gastrointestinal symptoms—nausea, diarrhoea, or constipation—as your body adapts to the GIP receptor activity [4]. These effects are typically mild to moderate and diminish within the first few weeks. Eating smaller, more frequent meals and avoiding high-fat foods can help manage symptoms during the transition period.

Comparing Efficacy: Switch From Ozempic to Wegovy vs Mounjaro

When deciding whether to switch from Ozempic to Wegovy or Mounjaro, comparative efficacy data provides valuable insight. The STEP 1 trial demonstrated that semaglutide 2.4 mg (Wegovy) achieved average weight loss of 14.9% versus 2.4% with placebo over 68 weeks [1]. In contrast, the SURMOUNT-1 trial showed tirzepatide 15 mg (Mounjaro) delivered average weight reductions of 20.9% versus 3.1% with placebo over 72 weeks [5]. While head-to-head trials directly comparing Wegovy 2.4 mg to Mounjaro 15 mg remain limited, available evidence suggests tirzepatide may offer incremental weight loss benefits for some patients.

However, individual response varies significantly, and switching from Ozempic to Wegovy may be preferable for patients who respond well to semaglutide and wish to continue the same active ingredient at a higher licensed dose. Conversely, those experiencing plateaued weight loss on Ozempic may benefit from switching from Ozempic to Mounjaro to access the dual incretin pathway. Your UK prescriber will assess your treatment history, comorbidities, and weight loss goals to recommend the most appropriate option.

UK Pricing and Availability When You Switch From Ozempic to Wegovy or Mounjaro

At Cured Pharmacy, patients switching from Ozempic to Wegovy benefit from transparent upfront pricing, with Wegovy available from £69.00 per month, subject to prescriber approval. New patients can Save £20 on their first order using code Weightlossnew, making the transition both clinically sound and cost-effective. All Wegovy prescriptions include a free online consultation with a UK-registered prescriber, completed in under three minutes, ensuring continuity of care during your switch.

For those switching from Ozempic to Mounjaro, Cured Pharmacy offers Mounjaro from £69.00 per month, again with the £69.00 first-order discount available. Both treatments are dispensed as genuine UK-licensed medicines, delivered in discreet packaging with next-day delivery options across the UK. Transparent pricing before consultation allows patients to make informed decisions without hidden costs, and our GPhC-registered pharmacy (9012511) under superintendent pharmacist Tarun Kumar ensures every prescription meets UK regulatory standards.

Prescription Requirements for Switching From Ozempic to Wegovy or Mounjaro

Both Wegovy and Mounjaro are prescription-only medicines in the UK, requiring clinical assessment by a UK-registered prescriber even if you are currently taking Ozempic. The online consultation reviews your medical history, current medications, weight loss progress, and any contraindications to ensure safe prescribing. Approval is not guaranteed and depends on clinical suitability, but most patients switching from Ozempic meet eligibility criteria for either Wegovy or Mounjaro.

Step-by-Step Guide to Switch From Ozempic to Wegovy or Mounjaro at Cured Pharmacy

Switching from Ozempic to Wegovy or Mounjaro through Cured Pharmacy follows a simple, clinically governed process. First, complete the free online consultation, providing details of your current Ozempic dose, treatment duration, weight loss achieved, and any side effects experienced. A UK-registered prescriber reviews your assessment, typically within hours, and determines whether Wegovy or Mounjaro is the most appropriate next step based on your individual circumstances.

Once approved, your prescription is dispensed by our GPhC-registered pharmacy and dispatched via next-day delivery in 100% discreet packaging. Your first Wegovy or Mounjaro injection should be administered one week after your final Ozempic dose, following the titration schedule provided by your prescriber. Ongoing clinical support is available via phone (+44 116 4646009) or email, ensuring you have expert guidance throughout your switch from Ozempic to Wegovy or Mounjaro. All follow-up prescriptions require repeat consultation to monitor progress and adjust dosing as needed.

Monitoring and Follow-Up After Switching From Ozempic to Wegovy or Mounjaro

Regular monitoring is essential after switching from Ozempic to Wegovy or Mounjaro to assess treatment response, manage side effects, and optimise dosing. UK clinical guidelines recommend reviewing weight loss progress every 4-12 weeks, with dose escalation contingent on tolerability and efficacy [3]. Patients should report any persistent nausea, vomiting, or abdominal pain to their prescriber, as these may indicate the need for dose adjustment or additional supportive measures.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., ... & SURPASS-2 Investigators. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
3. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). Retrieved from eMC. [accessed 15 August 2026]
4. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). Retrieved from eMC. [accessed 15 August 2026]
5. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & SURMOUNT-1 Investigators. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.